PR Newswire All News ReleasesQwen · 实盘不做把握 9/10不做原因:无增量信息
北京时间·🕒 发布 04:37:00·⟳ 抓取 04:38:28 +1m28s·⚡ 决策 08-28 04:40:17 +1m49s·60.6 天前
Pomerantz律所宣布对Hims & Hers Health (HIMS) 展开证券欺诈调查，基于已公开的FTC诉讼和Visa投诉事件
本次Pomerantz投资者招募稿与08-26已处理的Hagens Berman招募稿属同一具体催化(基于相同的FTC诉讼和Visa投诉事实)，无任何新增金额、监管进展、法院裁定、公司回应或指引变化。底层负面事件已在7/29(-14.73%)和8/24(-7.99%)被市场充分定价。
📄 原文PR Newswire All News Releases↗ 原文
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Hims & Hers Hea…
不做 Hims & Hers Health（HIMS.US）
本次Pomerantz投资者招募稿与08-26已处理的Hagens Berman招募稿、08-24已处理的Visa投诉事件属同一具体催化链，无任何新增监管进展、法院裁定、罚款金额、公司回应或指引变化。底层负面已在7/29(-14.73%)和8/24(-7.99%)被市场充分定价，无新增可交易edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Pomerantz律所发布投资者招募稿，调查Hims是否涉及证券欺诈。调查依据完全是两个已知事件：①2026-07-29 FTC起诉隐私违规(当日跌14.73%)；②2026-08-21 Visa投诉超标(8/24跌7.99%)。本系统已在08-24和08-26分别处理了这两个底层事件及另一家律所(Hagens Berman)的同类招募稿，均判定'不做'。本条无任何新增事实，属同一催化的重复信号。
🔎 新鲜度:最早出现 2026-08-27 · 扩散 low · price-in 风险 high ↗
先例如何影响了这次决策
对本次决策的影响:因判定为重复信号直接AVOID，未进入先例研究阶段
方向:不适用——本条为重复信号，无新增催化，不需要先例校准
涨幅量级:不适用
形态:不适用
工具执行结果 · 成功 2 · 降级 0 · 失败 0 · 取消 0
- fetch_decision_experience 成功 stock_tools HTTP · 841 ms
{ - search_processed_events 成功 stock_tools HTTP · 1,572 ms
{"result": "search_processed_events:agent query=`hims hers health ftc lawsuit securities fraud | hims visa customer complaints weight loss | pomerantz hims investigation`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 68.5/72 小时、11704 条本臂决策(完整)，返回 2 条候选。\n• 08-26 17:32 UTC(CST 08-27 01:32) [ticker] 不做 HIMS.US,META.US,SNA
原文全文
展开原文 · 2,499 字
NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE: HIMS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Hims and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On July 29, 2026, the Federal Trade Commission ("FTC") filed a lawsuit against Hims, accusing it of sharing customers' medical information with third-party advertisers. The FTC's criminal complaint accuses Hims of "deceptive and unlawful privacy practices," including sharing sensitive details about patient health with Meta Platforms, Snap and Facebook's parent company.
On this news, Hims' stock price fell $4.32 per share, or 14.73%, to close at $25.00 per share on July 29, 2026.
Then, on August 21, 2026, Bloomberg reported that Hims was put on notice by Visa Inc. for excessive customer complaints in its weight-loss subscription business, according to internal documents, adding to mounting scrutiny of its billing and cancellation policies. Reportedly, the Company was enrolled in Visa's Acquirer Monitoring Program after a surge of customer credit card disputes in July, according to the documents seen by Bloomberg. Each dispute will carry an $8 surcharge, resulting in a nearly $75,000 bill that will hit in September, the documents reportedly said.
On this news, Hims' stock price fell $2.70 per share, or 7.99%, to close at $31.08 per share on August 24, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
SOURCE Pomerantz LLP
The investigation concerns whether Hims and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On July 29, 2026, the Federal Trade Commission ("FTC") filed a lawsuit against Hims, accusing it of sharing customers' medical information with third-party advertisers. The FTC's criminal complaint accuses Hims of "deceptive and unlawful privacy practices," including sharing sensitive details about patient health with Meta Platforms, Snap and Facebook's parent company.
On this news, Hims' stock price fell $4.32 per share, or 14.73%, to close at $25.00 per share on July 29, 2026.
Then, on August 21, 2026, Bloomberg reported that Hims was put on notice by Visa Inc. for excessive customer complaints in its weight-loss subscription business, according to internal documents, adding to mounting scrutiny of its billing and cancellation policies. Reportedly, the Company was enrolled in Visa's Acquirer Monitoring Program after a surge of customer credit card disputes in July, according to the documents seen by Bloomberg. Each dispute will carry an $8 surcharge, resulting in a nearly $75,000 bill that will hit in September, the documents reportedly said.
On this news, Hims' stock price fell $2.70 per share, or 7.99%, to close at $31.08 per share on August 24, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
SOURCE Pomerantz LLP
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。